[go: up one dir, main page]

CL2015002817A1 - Formulación del l-5-metiltetrahidrofolato de calcio amorfo (l-5-mthf-ca). - Google Patents

Formulación del l-5-metiltetrahidrofolato de calcio amorfo (l-5-mthf-ca).

Info

Publication number
CL2015002817A1
CL2015002817A1 CL2015002817A CL2015002817A CL2015002817A1 CL 2015002817 A1 CL2015002817 A1 CL 2015002817A1 CL 2015002817 A CL2015002817 A CL 2015002817A CL 2015002817 A CL2015002817 A CL 2015002817A CL 2015002817 A1 CL2015002817 A1 CL 2015002817A1
Authority
CL
Chile
Prior art keywords
mthf
methyltetrahydrofolate
formulation
amorphous calcium
calcium
Prior art date
Application number
CL2015002817A
Other languages
English (en)
Inventor
Herrero Gonzalo Hernandez
Celestino Ronchi
Del Consuelo Isabel Díaz
Original Assignee
Chemo Res S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48045387&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015002817(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chemo Res S L filed Critical Chemo Res S L
Publication of CL2015002817A1 publication Critical patent/CL2015002817A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

FORMA FARMACEUTICA QUE COMPRENDE UNA CANTIDAD EFICAZ QUE VARIA DE 0,1 A 10 MG DE L-5-METILTETRAHIDROFOLATO DE CALCIO AMORFO COMO PRINCIPIO ACTIVO, CISTEINA COMO AGENTE ESTABILIZANTE Y OPCIONALMENTE OTROS AGENTES AUXILIARES; Y SU PROCEDIMIENTO DE FABRICACION.
CL2015002817A 2013-03-22 2015-09-21 Formulación del l-5-metiltetrahidrofolato de calcio amorfo (l-5-mthf-ca). CL2015002817A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13382106.6A EP2781214A1 (en) 2013-03-22 2013-03-22 Formulation of amorphous calcium L-5-methyltetrahydrofolate (L-5-MTHF-Ca)

Publications (1)

Publication Number Publication Date
CL2015002817A1 true CL2015002817A1 (es) 2016-03-11

Family

ID=48045387

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015002817A CL2015002817A1 (es) 2013-03-22 2015-09-21 Formulación del l-5-metiltetrahidrofolato de calcio amorfo (l-5-mthf-ca).

Country Status (10)

Country Link
US (1) US20160045440A1 (es)
EP (2) EP2781214A1 (es)
AR (1) AR095691A1 (es)
BR (1) BR112015024351A2 (es)
CA (1) CA2907746A1 (es)
CL (1) CL2015002817A1 (es)
MX (1) MX2015013535A (es)
PE (1) PE20151891A1 (es)
RU (1) RU2015139983A (es)
WO (1) WO2014146975A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3190112A4 (en) * 2014-09-04 2017-09-13 Lianyungang Jinkang Hexin Pharmaceutical Co., Ltd. Composition of (6s)-5-methyl tetrahydrofolic acid or salt thereof as well as preparation therefor and application thereof
CA2974953A1 (en) 2015-01-27 2016-08-04 La Vita Compounding Pharmacy Stable 5-methyltetrahydrofolate formulations to moderate methylenetetrahydrofolate reductase associated polymorphisms
WO2018049141A1 (en) 2016-09-12 2018-03-15 Steven Hoffman Compositions for treating dementia
CN109164182B (zh) * 2018-09-19 2021-06-11 无锡紫杉药业有限公司 一种对l-四氢叶酸对甲苯磺酸盐（6s）光学纯度的分析检测方法
EP3666260A1 (en) 2018-12-13 2020-06-17 Laboratorios Leon Farma SA Ethinyl estradiol-beta-cyclodextrin complex and process for preparing thereof
WO2021228788A1 (en) 2020-05-15 2021-11-18 Alfasigma S.P.A. Composition comprising methylfolate
CN113403355B (zh) * 2021-06-17 2022-05-31 山东大学 一种生物法生产l-5-甲基四氢叶酸的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223500A (en) * 1977-02-22 1993-06-29 Bioresearch S.P.A. Stable pharmaceutical composition of alkaline or alkaline earth 5-methyl tetrahydrofolate
US5124452A (en) * 1978-07-10 1992-06-23 Bioresearch S.P.A. Process for producing d,1-5-methyltetrahydrofolic acid and its salts
CH693905A5 (de) 1999-04-15 2004-04-15 Eprova Ag Stabile kristalline Salze von 5-Methyltetrahydrofolsäure.
UY29527A1 (es) 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.
CN101489563A (zh) * 2006-07-06 2009-07-22 拜耳先灵医药股份有限公司 用于避孕和预防先天性畸形风险的药物制剂
CH698729B1 (de) 2007-05-30 2009-10-15 Cerbios Pharma Sa Stabile, kristalline (6S)-N(5)-Methyl-5, 6,7,8-tetrahydrofolsäure.
CN102813656B (zh) * 2012-09-13 2014-05-07 广东岭南制药有限公司 5-甲基四氢叶酸或其盐的稳定药物组合物

Also Published As

Publication number Publication date
US20160045440A1 (en) 2016-02-18
CA2907746A1 (en) 2014-09-25
RU2015139983A (ru) 2017-04-25
EP2976066A1 (en) 2016-01-27
EP2781214A1 (en) 2014-09-24
BR112015024351A2 (pt) 2017-07-18
AR095691A1 (es) 2015-11-04
MX2015013535A (es) 2016-05-31
PE20151891A1 (es) 2015-12-20
WO2014146975A1 (en) 2014-09-25

Similar Documents

Publication Publication Date Title
CL2015002817A1 (es) Formulación del l-5-metiltetrahidrofolato de calcio amorfo (l-5-mthf-ca).
CL2015002710A1 (es) Composiciones de arni contra el componente c5 del complemento y métodos para su uso.
CL2016002372A1 (es) Cenicriviroc para el tratamiento de la fibrosis.
MX382405B (es) Método para suministrar un agente activo.
EA201492290A1 (ru) Составы и способы для вагинальной доставки антипрогестинов
MX2016006025A (es) Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres.
CU24397B1 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b
UY35299A (es) Formulación combinada de dos compuestos antivirales
CL2017001964A1 (es) Encapsulado de agentes activos de alta potencia.
NI201500118A (es) Imidazopiridazinas sustituidas
AR098168A1 (es) Formulación estable de insulina glulisina
DOP2016000007A (es) Pirazolpiridinas sustituidas
CO2017012645A2 (es) Agente antihipertensivo que comprende s-1-propenilcisteína o una sal del mismo como ingrediente activo
GT201700280A (es) Formulación sólida oral que contiene irinotecán y método de preparación de la misma
UY35848A (es) Tienopirimidinas
PH12015502282A1 (en) Alpha-2 adrenoceptor and sigma receptor ligand combinations
BR112015029894A2 (pt) forma de dosagem farmacêutica sólida
CL2015001748A1 (es) Formulaciones antiparasitarias transdermicas
CL2016001130A1 (es) Composiciones sólidas de triglicéridos y usos de estas
CL2015003460A1 (es) Composiciones oftálmicas acuosas tópicas que contienen un derivado de 1h-indol-1-carboxamida y uso de estas para el tratamiento de una enfermedad oftálmica
MX2017009863A (es) Agente preventivo y/o terapeutico de enfermedad inmune.
SV2016005308A (es) Composiciã“n farmacã‰utica para el tratamiento de alopatã�as relacionadas con el dolor, usando como agente activo al ketorolaco trometamina y clorhidrato de tramadol
ECSP15005163A (es) Composiciones líquidas orales pediátricas que contienen nepadutant
UY35528A (es) Moduladores del receptor de la progesterona para uso en la terapia de fibromas uterinos
PE20151432A1 (es) Formulaciones de lorazepam de liberacion sostenida